Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11741059 | 0.87 | ACHE (0.50) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5747611 | 0.85 | ACHE (0.48) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11735248 | 0.83 | ACHE (0.57) | ACHE | |
| SCHEMBL10839834 | 0.81 | CHRNB2 (0.51) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11736597 | 0.81 | ACHE (0.57) | ACHE | |
| SCHEMBL10021633 | 0.79 | ACHE (0.44) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20328706 | 0.79 | ACHE (0.59) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9313040 | 0.78 | ACHE (0.42) | ACHE | |
| SCHEMBL2592697 | 0.76 | ACHE (0.67) | ACHE | |
| SCHEMBL10827960 | 0.76 | ACHE (0.78) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030545-B1 | AMINO ACID DERIVATIVES | MEDIMMUNE LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| CN-105980350-B | Amino acid derivativges | 米迪缪尼有限公司 | 2018-11-27 | — | — | CN | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| CN-105980350-A | Amino acid derivatives | 米迪缪尼有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-3030545-A2 | AMINO ACID DERIVATIVES | Medimmune Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019192-A2 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176811-A1 | Amino Acid Derivatives | BCAT2, BCAT1, DAO | ACHE 4790/4885CHRNB2 4719/4885CHRNB4 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.